2024
Effects of dapagliflozin on body composition and its relation to hemodynamics in heart failure with preserved ejection fraction: the CAMEO-DAPA randomized clinical trial
Naser J, Tada A, Harada T, Reddy Y, Carter R, Testani J, Jensen M, Borlaug B. Effects of dapagliflozin on body composition and its relation to hemodynamics in heart failure with preserved ejection fraction: the CAMEO-DAPA randomized clinical trial. European Heart Journal 2024, 45: ehae666.1044. DOI: 10.1093/eurheartj/ehae666.1044.Peer-Reviewed Original ResearchPulmonary capillary wedge pressureFat-free massEffects of dapagliflozinDual-energy X-ray absorptiometryBone mineral contentTrunk fatBody compositionCardiac hemodynamicsHeart failureExercise pulmonary capillary wedge pressureTotal body fat-free massHemodynamic effectsBody fatEnergy X-ray absorptiometryReduced fat-free massWeeks of dapagliflozinDevelopment of heart failureBody fat-free massPlacebo-controlled studyFavorable hemodynamic effectsCapillary wedge pressureX-ray absorptiometryPlasma volumeDecreased risk of hospitalizationTotal body fatMechanistic Differences between Torsemide and Furosemide.
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang W, Collins S, Velazquez E, Mentz R, Wilson F, Turner J, Wilcox C, Ellison D, Fang J, Testani J. Mechanistic Differences between Torsemide and Furosemide. Journal Of The American Society Of Nephrology 2024 PMID: 39196651, DOI: 10.1681/asn.0000000000000481.Peer-Reviewed Original ResearchTorsemide groupDiuretic doseTubular site of actionHigher diuretic dosesDose of furosemideProportion of dosesOral furosemideSite of actionPrescribed doseNeurohormonal activationMechanistic substudyClinical outcomesPharmacodynamic advantagesKidney dysfunctionPharmacodynamic parametersKidney functionRandomized trialsNatriuresisTubular sitesFurosemideTorsemideDoseTRANSFORM-HFPlasma volumeBody weight
2020
Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study
Akiyama E, Cinotti R, Čerlinskaitė K, Van Aelst LNL, Arrigo M, Placido R, Chouihed T, Girerd N, Zannad F, Rossignol P, Badoz M, Launay J, Gayat E, Cohen‐Solal A, Lam CSP, Testani J, Mullens W, Cotter G, Seronde M, Mebazaa A. Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study. ESC Heart Failure 2020, 7: 996-1006. PMID: 32277607, PMCID: PMC7261539, DOI: 10.1002/ehf2.12645.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionTricuspid annular plane systolic excursionNeutrophil Gelatinase-Associated LipocalinVenous pressureAHF patientsHFrEF patientsCardiac chamber dimensionsEchocardiographic parametersDyspnea patientsHeart failureNatriuretic peptidePlasma volumeMid-regional pro-atrial natriuretic peptideAcute heart failure patientsDiastolic Heart Failure StudyAnnular plane systolic excursionPro-atrial natriuretic peptideB-type natriuretic peptideE-wave deceleration timeInferior vena cava diameterAcute heart failureDiastolic heart failureGelatinase-Associated LipocalinGlomerular filtration rateHeart failure patients